NCT05883748View on ClinicalTrials.gov

Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with EPP

PHASE2/PHASE3Enrolling by invitationINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 31, 2023

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Erythropoietic Protoporphyria
Interventions
DRUG

DISC-1459

DISC-1459 dose level 1

DRUG

DISC-1459

DISC-1459 dose level 2

Trial Locations (11)

2050

Royal Prince Alfred Hospital, Camperdown

3050

The Royal Melbourne Hospital, Parkville

10029

Mount Sinai Hospital, New York

19141

Einstein Medical Center, Philadelphia

27157

Atrium Health Wake Forest Baptist, Winston-Salem

33136

University of Miami Miller School of Medicine, Miami

35233

University of Alabama Hospital, Birmingham

77550

University of Texas, Galveston

94117

University of California San Francisco, San Francisco

98109

Fred Hutchinson Cancer Center, Seattle

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Disc Medicine, Inc
All Listed Sponsors
lead

Disc Medicine, Inc

INDUSTRY

NCT05883748 - Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with EPP | Biotech Hunter | Biotech Hunter